Posters & Publications

Jun 6 2022, ASCO Poster, Melanoma

Glycoproteomics as a powerful liquid biopsy-based predictor of checkpoint-inhibitor treatment benefit in metastatic malignant melanoma

Learn More →
Jun 5 2022, ASCO Poster, Sarcoma

Serum glycoproteomic signatures predict overall survival in bone and soft tissue sarcoma patients treated with immune checkpoint inhibitor therapy

Learn More →
Jun 5 2022, ASCO Online Publication, Immune Checkpoint Inhibitors

Clinicians’ perspective on use of immune checkpoint inhibitors and related biomarkers for solid tumors

Learn More →
Show More


June 2 2022

InterVenn Biosciences Announces New Data Validating the Clinical Performance of DAWN™ IO Melanoma

InterVenn® Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, today announced new data showing that its new DAWN IO Melanoma test accurately assesses and classifies advanced melanoma patients as likely or unlikely to benefit from immune checkpoint inhibitor therapies: either pembrolizumab alone or ipilimumab in combination with nivolumab.
Learn More →
May 6 2022

InterVenn to Present New Clinical Data at ASCO 2022

InterVenn Biosciences, the leader in applied glycoproteomics, today announced that it will present new clinical data detailing the success of its novel approach to liquid biopsy testing in multiple cancer indications at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting. The meeting will take place from June 3 to June 7 at McCormick Place in Chicago.
Learn More →


The need for more informative biomarkers, and for deeper insights into the nature of most diseases than provided by genomics, has become increasingly clear. InterVenn is addressing this need for a different approach with a powerful new biomarker discovery platform based on interrogating the glycoproteome as a previously unexplored, yet ubiquitously important layer of biology. Along with nucleic acids and proteins, glycans represent a third ‘alphabet of biology’. Exploring this additional class of information-carrying biomolecules opens an entirely new, vast repertoire of analytes to drive next-generation precision medicine.

Download pdf